Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer
Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the Company´s Chief Scientific Officer. Irene Knuesel brings longstanding experience in CNS research, drug discovery and development. She is Mehr